[H10] HRP-conjugated Goat Anti-Human Apolipoprotein E50H-G1a
|Concentration:||1 mg/ml (OD 1.35 / 280 nm)|
|Antigen:||Human Apolipoprotein E|
|Buffer:||50 mM PBS, 0.1 M NaCl, and 0.01% Thiomersal, pH 7.4.|
|Specificity||Specifically binds to human apo E. Dilution for immunoblot and ELISA range: 1,000 to 8,000.|
|Use:||The antibody can be used for detection of apo E in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.|
|Storage:||-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.|
|Form:||Freeze dried powder|
|Stabilizer:||10 mg / ml Bovine Serum Albumin.|
Freeze-dried product should be stored refrigerated until opened. After opening, restore to suggested ml volume with distilled water. If it is not completely clear after standing for 1-2 hours at room temperature, centrifuge the product. It is stable for several weeks at 4°C as an undiluted liquid. Do not use for more than one day after dilution. For extended storage after reconstitution, we suggest aliquot to avoid repeated freezing and thawing; or the addition of an equal volume of glycerol to make a final glycerol concentration of 50%, followed by storage at -20°C. The concentration of protein and buffer salts will decrease to one-half of the original after the addition of glycerol.
*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
Apo E contains 299 amino acid residues. It is a 34-37 kDa glycosylated protein (Rall et al., 1983).
Apo E is involved with triglyceride, phospholipid, cholesteryl ester, and cholesterol transport in and out of cells and is a ligand for LDL receptors. Apo E has also been implicated in immune and nerve degeneration. It has been found to suppress lymphocyte proliferation. Late-onset familial and sporadic Alzheimer disease patients have been found to have a higher occurrence of one of the three common Apo E isoforms, Apo E4. The Apo E4 isoform has been detected in senile plaques and neurofibrillary tangles of Alzheimer disease patients. Apo E4 is associated with rapid chylomicron-remnant clearance and increased total cholesterol levels.
Rall, S C, K H Weisgraber, T L Innerarity, T P Bersot, R W Mahley, and C B Blum. "Identification of a New Structural Variant of Human Apolipoprotein E, E2(Lys146 Leads to Gln), in a Type III Hyperlipoproteinemic Subject with the E3/2 Phenotype." Journal of Clinical Investigation 72.4 (1983): 1288-297.
|[H10]||2017||Yamauchi, Kazuyoshi; Ebihara, Yuka; Kawakami, Yasushi (2017): Redox status of serum apolipoprotein E and its impact on HDL cholesterol levels. In Clinical biochemistry 50 (13-14), pp. 777–783. DOI: 10.1016/j.clinbiochem.2017.03.021.|
|[H10]||2009||Carmel, Jean-François; Tarnus, Evelyne; Cohn, Jeffrey S.; Bourdon, Emmanuel; Davignon, Jean; Bernier, Lise (2009): High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes. In J. Cell. Biochem. 106 (4), pp. 608–617. DOI: 10.1002/jcb.22037.|
|[H10]||2009||Gillard, Baiba K.; Lin, Hu-Yu Alice; Massey, John B.; Pownall, Henry J. (2009): Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. In Biochimica et biophysica acta 1791 (12), pp. 1125–1132. DOI: 10.1016/j.bbalip.2009.07.004.|
|[H10]||2009||Osman, Eyman; Evans, Vanessa; Graham, Ian R.; Athanasopoulos, Takis; McIntosh, Jenny; Nathwani, Amit C. et al. (2009): Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice. In Atherosclerosis 204 (1), pp. 121–126. DOI: 10.1016/j.atherosclerosis.2008.08.043.|
|[H10]||2009||Tarnus, Evelyne; Wassef, Hanny; Carmel, Jean-François; Rondeau, Philippe; Roche, Marjolaine; Davignon, Jean et al. (2009): Apolipoprotein E limits oxidative stress-induced cell dysfunctions in human adipocytes. In FEBS Letters 583 (12), pp. 2042–2048. DOI: 10.1016/j.febslet.2009.05.016.|
|[H10]||2008||Zeitouni, Suzanne; Ford, Brian S.; Harris, Sean M.; Whitney, Mandolin J.; Gregory, Carl A.; Prockop, Darwin J. (2008): Pharmaceutical induction of ApoE secretion by multipotent mesenchymal stromal cells (MSCs). In BMC Biotechnol 8 (1), p. 75. DOI: 10.1186/1472-6750-8-75.|
|[H10]||2006||Yokoyama, Yuichiro; Kuramitsu, Yasuhiro; Takashima, Motonari; Iizuka, Norio; Terai, Shuji; Oka, Masaaki et al. (2006): Protein level of apolipoprotein E increased in human hepatocellular carcinoma. In International journal of oncology 28 (3), pp. 625–631.|
|[H10]||2005||Bouchard, Catherine; Dubuc, Geneviève; Davignon, Jean; Bernier, Lise; Cohn, Jeffrey S. (2005): Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells. In Atherosclerosis 178 (2), pp. 257–264. DOI: 10.1016/j.atherosclerosis.2004.09.014.|
|[H10]||2004||Wassef, Hanny; Bernier, Lise; Davignon, Jean; Cohn, Jeffrey S. (2004): Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells. In J. Nutr. 134 (11), pp. 2935–2941. DOI: 10.1093/jn/134.11.2935.|